Downregulation of SASH1 correlates with tumor progression and poor prognosis in ovarian carcinoma

Ren,Xiaoyan; Liu,Yifei; Tao,Yumei; Zhu,Guoxiang; Pei,Meilan; Zhang,Jianguo; Liu,Jian

doi:10.3892/ol.2016.4345

Downregulation of SASH1 correlates with tumor progression and poor prognosis in ovarian carcinoma

Authors:
- Xiaoyan Ren
- Yifei Liu
- Yumei Tao
- Guoxiang Zhu
- Meilan Pei
- Jianguo Zhang
- Jian Liu
View Affiliations

Affiliations: Department of Pathology, Maternal and Child Health Care Hospital of Nantong, Nantong, Jiangsu 226018, P.R. China, Department of Pathology, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Obstetrics, Maternal and Child Health Care Hospital of Nantong, Nantong, Jiangsu 226018, P.R. China, Department of Chemotherapy, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China
Published online on: March 17, 2016 https://doi.org/10.3892/ol.2016.4345
Pages: 3123-3130

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

SAM- and SH3-domain containing 1 (SASH1) is a recently identified tumor suppressor gene that is required in the tumorigenesis of breast and other solid carcinomas. The SASH1 protein contains SH3 and SAM domains, indicating that it may serve an important role in intracellular signal transduction. The purpose of the present study was to investigate the expression of SASH1 in ovarian carcinoma and the correlation between its expression with clinical pathological features and clinical significance, and the effect of SASH1 on cell proliferation, apoptosis and migration of ovarian SKOV3 cells. The human ovarian carcinoma tissues and adjacent normal tissues were collected following surgery. Reverse transcription‑quantitative polymerase chain reaction and western blot analysis were used to detect the expression levels of SASH1 mRNA and protein, respectively. The expression levels of SASH1 mRNA and protein in ovarian carcinoma tissues were significantly lower than that observed in adjacent normal tissues (P<0.05). The expression levels of SASH1 in samples from patients without lymph nodes metastasis and patients with early FIGO stage was lower than those with lymph nodes metastasis and patients with advanced FIGO stage (P<0.05). Flow cytometry analysis and Transwell invasion chamber experiments were used to investigate the effect of SASH1 on the cell proliferation, apoptosis and migration of SKOV3 cells. The recombinant plasmid pcDNA3.1‑SASH1 was constructed and transfected into SKOV3 cells. In addition, the SKOV3 cells in the pcDNA3.1‑SASH1 group exhibited significantly reduced cell growth, proliferation, and migration ability compared to the empty vector group and normal group (P<0.01). There were a greater number of apoptotic cells in the pcDNA3.1‑SASH1 group compared to the empty vector group and normal group (P<0.01). Taken together, these results indicated that SASH1 may be a tumor suppressor gene in ovarian carcinoma, and SASH1 expression inhibited growth, proliferation and migration, and enhanced apoptosis of SKOV3 cells.

View Figures

View References

1	Schwab CL, English DP, Roque DM, Pasternak M and Santin AD: Past, present and future targets for immunotherapy in ovarian cancer. Immunotherapy. 6:1279–1293. 2014. View Article : Google Scholar : PubMed/NCBI
2	Seidman JD, Vang R, Ronnett BM, Yemelyanova A and Cosin JA: Distribution and case-fatality ratios by cell-type for ovarian carcinomas: A 22-year series of 562 patients with uniform current histological classification. Gynecol Oncol. 136:336–340. 2014. View Article : Google Scholar : PubMed/NCBI
3	Thériault BL, Cybulska P, Shaw PA, Gallie BL and Bernardini MQ: The role of KIF14 in patient-derived primary cultures of high-grade serous ovarian cancer cells. J Ovarian Res. 7:1232014. View Article : Google Scholar : PubMed/NCBI
4	Ottolina J, Ferrandina G, Gadducci A, Scollo P, Lorusso D, Giorda G, Breda E, Savarese A, Candiani M, Zullo F and Mangili G: Is the endometrial evaluation routinely required in patients with adult granulosa cell tumors of the ovary? Gynecol Oncol. 136:230–234. 2015. View Article : Google Scholar : PubMed/NCBI
5	Pham E, Birrer MJ, Eliasof S, Garmey E, Lazarus D, Lee CR, Man S, Matulonis UA, Peters CG, Xu P, et al: Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clin Cancer Res. 21:808–818. 2015. View Article : Google Scholar : PubMed/NCBI
6	Yang X, Shen F, Hu W, Coleman RL and Sood AK: New ways to successfully target tumor vasculature in ovarian cancer. Curr Opin Obstet Gynecol. 27:58–65. 2015. View Article : Google Scholar : PubMed/NCBI
7	Bian Z, Yu Y, Quan C, Guan R, Jin Y, Wu J, Xu L, Chen F, Bai J, Sun W and Fu S: RPL13A as a reference gene for normalizing mRNA transcription of ovarian cancer cells with paclitaxel and 10-hydroxycamptothecin treatments. Mol Med Rep. 11:3188–3194. 2015.PubMed/NCBI
8	Ye H, Karim AA and Loh XJ: Current treatment options and drug delivery systems as potential therapeutic agents for ovarian cancer: A review. Mater Sci Eng C Mater Biol Appl. 45:609–619. 2014. View Article : Google Scholar : PubMed/NCBI
9	Sun X, Lou LG, Sui DH and Wu XH: Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells. Asian Pac J Cancer Prev. 15:9939–9943. 2014. View Article : Google Scholar : PubMed/NCBI
10	Shen H, Cai M, Zhao S, Wang H, Li M, Yao S and Jiang N: CYR61 overexpression associated with the development and poor prognosis of ovarian carcinoma. Med Oncol. 31:1172014. View Article : Google Scholar : PubMed/NCBI
11	Vermeersch KA, Wang L, McDonald JF and Styczynski MP: Distinct metabolic responses of an ovarian cancer stem cell line. BMC Syst Biol. 8:1342014. View Article : Google Scholar : PubMed/NCBI
12	Chen K, Ma H, Li L, Zang R, Wang C, Song F, Shi T, Yu D, Yang M, Xue W, et al: Genome-wide association study identifies new susceptibility loci for epithelial ovarian cancer in Han Chinese women. Nat Commun. 5:46822014. View Article : Google Scholar : PubMed/NCBI
13	Zeller C, Hinzmann B, Seitz S, Prokoph H, Burkhard-Goettges E, Fischer J, Jandrig B, Schwarz LE, Rosenthal A and Scherneck S: SASH1: A candidate tumor suppressor gene on chromosome 6q24.3 is downregulated in breast cancer. Oncogene. 22:2972–2983. 2003. View Article : Google Scholar : PubMed/NCBI
14	Rimkus C, Martini M, Friederichs J, Rosenberg R, Doll D, Siewert JR, Holzmann B and Janssen KP: Prognostic significance of downregulated expression of the candidate tumour suppressor gene SASH1 in colon cancer. Br J Cancer. 95:1419–1423. 2006. View Article : Google Scholar : PubMed/NCBI
15	Gambetta MC and Muller J: O-GlcNAcylation prevents aggregation of the polycomb group repressor polyhomeotic. Dev Cell. 31:629–639. 2014. View Article : Google Scholar : PubMed/NCBI
16	McCorvie TJ, Kopec J, Hyung SJ, Fitzpatrick F, Feng X, Termine D, Strain-Damerell C, Vollmar M, Fleming J, Janz JM, et al: Inter-domain communication of human cystathionine beta synthase: Structural basis of S-adenosyl-L-methionine activation. J Biol Chem. 289:36018–36030. 2014. View Article : Google Scholar : PubMed/NCBI
17	Courcet JB, Elalaoui SC, Duplomb L, Tajir M, Riviere JB, Thevenon J, Gigot N, Marle N, Aral B, Duffourd Y, et al: Autosomal-recessive SASH1 variants associated with a new genodermatosis with pigmentation defects, palmoplantar keratoderma and skin carcinoma. Eur J Hum Genet. 23:957–962. 2015. View Article : Google Scholar : PubMed/NCBI
18	Dauphinee SM, Clayton A, Hussainkhel A, Yang C, Park YJ, Fuller ME, Blonder J, Veenstra TD and Karsan A: SASH1 is a scaffold molecule in endothelial TLR4 signaling. J Immunol. 191:892–901. 2013. View Article : Google Scholar : PubMed/NCBI
19	Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, Olmos D, Garrett CR, et al: Anti-tumour activity in RAS-driven tumours by blocking AKT and MEK. Clin Cancer Res. 21:739–748. 2015. View Article : Google Scholar : PubMed/NCBI
20	Takata A, Terauchi M, Hiramitsu S, Uno M, Wakana K and Kubota T: Dkk-3 induces apoptosis through mitochondrial and Fas death receptor pathways in human mucinous ovarian cancer cells. Int J Gynecol Cancer. 25:372–379. 2015. View Article : Google Scholar : PubMed/NCBI
21	Zhao X, Zhou Y, Nie M, Xian S, Chen H, Wen Y, Zhang L, Huang Y, Chen M and Wang S: EMSY promoted the growth and migration of ovarian cancer cells. Tumour Biol. 36:3085–3092. 2015. View Article : Google Scholar : PubMed/NCBI
22	Meng Q, Zheng M, Liu H, Song C, Zhang W, Yan J, Qin L and Liu X: SASH1 regulates proliferation, apoptosis and invasion of osteosarcoma cell. Mol Cell Biochem. 373:201–210. 2013. View Article : Google Scholar : PubMed/NCBI
23	Lin S, Zhang J, Xu J, Wang H, Sang Q, Xing Q and He L: Effects of SASH1 on melanoma cell proliferation and apoptosis in vitro. Mol Med Rep. 6:1243–1248. 2012.PubMed/NCBI
24	Yang L, Liu M, Gu Z, Chen J, Yan Y and Li J: Overexpression of SASH1 related to the decreased invasion ability of human glioma U251 cells. Tumour Biol. 33:2255–2263. 2012. View Article : Google Scholar : PubMed/NCBI
25	Zeppernick F and Meinhold-Heerlein I: The new FIGO staging system for ovarian, fallopian tube and primary peritoneal cancer. Arch Gynecol Obstet. 290:839–842. 2014. View Article : Google Scholar : PubMed/NCBI
26	Wang S, Zhao X, Wang J, Wen Y, Zhang L, Wang D, Chen H, Chen Q and Xiang W: Upregulation of microRNA-203 is associated with advanced tumor progression and poor prognosis in epithelial ovarian cancer. Med Oncol. 30:6812013. View Article : Google Scholar : PubMed/NCBI
27	Sasano T, Mabuchi S, Kuroda H, Kawano M, Matsumoto Y, Takahashi R, Hisamatsu T, Sawada K, Hashimoto K, Isobe A, et al: Preclinical efficacy for AKT targeting in clear cell carcinoma of the ovary. Mol Cancer Res. 13:795–806. 2015. View Article : Google Scholar : PubMed/NCBI
28	Cannistra SA: Cancer of the ovary. N Engl J Med. 351:2519–2529. 2004. View Article : Google Scholar : PubMed/NCBI
29	Colombo PE, Boustta M, Poujol S, Jarlier M, Bressolle F, Teulon I, Ladjemi MZ, Pinguet F, Rouanet P and Vert M: Intraperitoneal administration of novel doxorubicin loaded polymeric delivery systems against peritoneal carcinomatosis: Experimental study in a murine model of ovarian cancer. Gynecol Oncol. 122:632–640. 2011. View Article : Google Scholar : PubMed/NCBI
30	Pereira A, Pérez-Medina T, Magrina JF, Magtibay PM, Rodríguez-Tapia A, Peregrin I, Mendizabal E and Ortiz-Quintana L: International federation of gynecology and obstetrics staging classification for cancer of the ovary, fallopian tube and peritoneum: Estimation of survival in patients with node-positive epithelial ovarian cancer. Int J Gynecol Cancer. 25:49–54. 2015. View Article : Google Scholar : PubMed/NCBI
31	Grigoriadis C, Eleftheriades M, Panoskaltsis T, Bacanu AM, Vitoratos N, Kondi-Pafiti A, Tsangkas A, Tympa A and Hassiakos D: Ovarian cancer diagnosed during pregnancy: Clinicopathological characteristics and management. G Chir. 35:69–72. 2014.PubMed/NCBI
32	Baratta MG, Schinzel AC, Zwang Y, Bandopadhayay P, Bowman-Colin C, Kutt J, Curtis J, Piao H, Wong LC, Kung AL, et al: An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci USA. 112:232–237. 2015. View Article : Google Scholar : PubMed/NCBI
33	Song Y, Xin X, Zhai X, Xia Z and Shen K: Sequential combination therapy with flavopiridol and autocatalytic caspase-3 driven by amplified hTERT promoter synergistically suppresses human ovarian carcinoma growth in vitro and in mice. J Ovarian Res. 7:1212014. View Article : Google Scholar : PubMed/NCBI
34	Taube ET, Denkert C, Pietzner K, Dietel M, Sehouli J and Darb-Esfahani S: Prognostic impact of neuroendocrine differentiation in high-grade serous ovarian carcinoma. Virchows Arch. 466:333–342. 2015. View Article : Google Scholar : PubMed/NCBI
35	Chao A, Lai CH, Chen HC, Lin CY, Tsai CL, Tang YH, Huang HJ, Lin CT, Chen MY, Huang KG, et al: Serum microRNAs in clear cell carcinoma of the ovary. Taiwan J Obstet Gynecol. 53:536–541. 2014. View Article : Google Scholar : PubMed/NCBI
36	Zhu L, Hu Z, Liu J, Gao J and Lin B: Gene expression profile analysis identifies metastasis and chemoresistance-associated genes in epithelial ovarian carcinoma cells. Med Oncol. 32:4262015. View Article : Google Scholar : PubMed/NCBI
37	Jeong HJ, Kim HJ, Lee EH, Lee HW and Kim MK: Perimenopausal ovarian carcinoma patient with subclavian node metastasis proven by immunohistochemistry. J Menopausal Med. 20:43–46. 2014. View Article : Google Scholar : PubMed/NCBI
38	Nafisi H, Cesari M, Karamchandani J, Balasubramaniam G and Keith JL: Metastatic ovarian carcinoma to the brain: An approach to identification and classification for neuropathologists. Neuropathology. 35:122–129. 2015. View Article : Google Scholar : PubMed/NCBI
39	Resta G, Vedana L, Marino S, Scagliarini L, Bandi M and Anania G: Isolated splenic metastasis of ovaric cancer. Case report and literature review. G Chir. 35:181–184. 2014.PubMed/NCBI
40	Kumar PM and Manisha M: Epidural hematoma secondary to solitary skull metastasis from an ovarian carcinoma. Asian J Neurosurg. 9:112–114. 2014. View Article : Google Scholar : PubMed/NCBI
41	Longo R, Platini C, Eid N, Elias-Matta C, Buda T, Nguyen D and Quétin P: A late, solitary brain metastasis of epithelial ovarian carcinoma. BMC Cancer. 14:5432014. View Article : Google Scholar : PubMed/NCBI